Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-14T10:08:58.321Z Has data issue: false hasContentIssue false

Section 6 - Thrombophilia and Fetal Loss

Published online by Cambridge University Press:  01 February 2018

Edited by
Sue Pavord  and
Beverley Hunt
Sue Pavord
Affiliation:
University of Oxford
Beverley Hunt
Affiliation:
King's College London
Get access
Type
Chapter
Information
The Obstetric Hematology Manual , pp. 177 - 196
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

Miyakis, S, Lockshin, MD, Atsumi, T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Hemostasis 2006; 4: 295–306.Google Scholar
McMahon, MA, Keogan, M, O’Connell, P, Kearns, G. The prevalence of antiphospholipid antibody syndrome among systemic lupus erythematosus patients. Irish Medical Journal 2006; 99: 296–298.Google Scholar
Noori, AS, Jassim, NA, Gorial, FI. Prevalence of antiphospholipid antibodies in sample of Iraqi patients with systemic lupus erythematosus: a cross sectional study. American Journal of Clinical Medicine Research 2013; 1: 61–64.CrossRefGoogle Scholar
Galli, M, Luciani, D, Bertolini, G, Barbui, T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827–1832.Google Scholar
Pengo, V, Ruffatti, A, Legnani, C et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118(17): 4714–4718.Google Scholar
Meroni, PL, Borghi, MO, Raschi, E, Tedesco, F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nature Reviews Rheumatology 2011; 7(6): 330–339.Google Scholar
Girardi, G, Redecha, P, Salmon, JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine 2004; 10: 1222–1226.CrossRefGoogle ScholarPubMed
Wilson, WA, Gharavi, AE, Koike, T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis and Rheumatism 1999; 42: 1309–1311.Google Scholar
Cervera, R, Piette, JC, Font, J et al. Euro-Phospholipids Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and Rheumatism 2002; 46: 1019–1027.CrossRefGoogle Scholar
Asherson, RA, Khamashta, MA, Ordi-Ros, J et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68: 366–374.CrossRefGoogle Scholar
Yetman, DL, Kutteh, WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertility and Sterility 1996; 66: 540–546.Google Scholar
Rai, RS, Clifford, K, Cohen, H, Regan, L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Human Reproduction 1995; 10: 3301–3304.Google Scholar
Dreyfus, M, Hedelin, G, Kutnahorsky, R et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstetrics and Gynecology 2001; 97: 29–34.Google Scholar
Diz-Küçükkaya, R, Hacihanefioglu, A, Yenerel, M et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760–1764.CrossRefGoogle ScholarPubMed
Brandt, JT, Triplett, DA, Alving, B, Scharrer, I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thrombosis and Hemostasis 1995; 74: 1185–1190.Google Scholar
Harris, EN, Pierangeli, SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269–275.Google Scholar
Cowchock, FS, Reece, EA, Balaban, D et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisone with low-dose heparin treatment. American Journal of Obstetrics and Gynecology 2003; 101: 1319–1332.Google Scholar
Rai, R, Cohen, H, Dave, M, Regan, L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. British Medical Journal 1997; 314: 253–257.CrossRefGoogle ScholarPubMed
Kutteh, WH. Antiphospholipid antibody associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low dose aspirin alone. American Journal of Obstetrics and Gynecology 1996; 174: 1584–1589.Google Scholar
Izmirly, PM, Costedoat-Chalumeau, N, Pisoni, C et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro associated cardiac manifestations of neonatal lupus. Circulation 2012; 126(1): 76–82.CrossRefGoogle ScholarPubMed
Empson, M, Lassere, M, Craig, J, Scott, J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database of Systematic Reviews 2005; (2): 002859.Google Scholar
Farquharson, RG, Quenby, S, Greaves, M. Antiphospholipid syndrome in pregnancy: a randomised controlled trial of treatment. Obstetrics and Gynecology 2002; 100: 408–413.CrossRefGoogle ScholarPubMed
Mak, A, Cheung, MWL, Cheak, AA, Ho, RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology 2010; 49: 281–288.Google Scholar
Le Thi Huong, D, Weschler, B, Vauthier-Brouzes, D et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosis and/or the antiphospholipid syndrome. Rheumatology 2006; 45: 332–338.CrossRefGoogle ScholarPubMed
Triolo, G, Ferrante, A, Ciccia, F et al. Randomised study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss. Arthritis and Rheumatism 2003; 48: 728–731.CrossRefGoogle ScholarPubMed
Cervera, R, Asherson, RA, Font, J et al. Chorea in the antiphospholipid syndrome: Clinical, radiologic and immunologic characteristics of 50 patients from our clinics and recent literature. Medicine 1997; 76(3): 203–212.CrossRefGoogle ScholarPubMed
Gris, JC, Bouvier, S, Molinari, N et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012; 119(11): 2624–2632.CrossRefGoogle ScholarPubMed
Boffa, MC, Lachassine, E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus 2007; 16: 634–641.CrossRefGoogle ScholarPubMed

References

Pijnenborg, R, Vercruysse, L, Brosens, I. Deep placentation. Best Practice & Research Clinical Obstetrics & Gynaecology 2011; 25(3): 273–285.Google Scholar
Redecha, P, Franzke, C, Ruf, W, Mackman, N, Girardi, G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. Journal of Clinical Investigation 2008; 118(10): 3453–3461.Google Scholar
De Jong, PG, Goddijn, M, Middeldorp, S. Antithrombotic therapy for pregnancy loss. Human Reproduction Update 2013; 19(6): 656–673.Google Scholar
Robertson, L, Wu, O, Langhorne, P et al. Thrombophilia in pregnancy: A systematic review. British Journal of Haematology 2006; 132: 171–196.CrossRefGoogle ScholarPubMed
Rodger, MA, Walker, MC, Smith, GN et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. Journal of Thrombosis and Haemostasis 2014; 12: 469–478.Google Scholar
Van Mens, TE, Levi, M, Middeldorp, S. Evolution of factor V Leiden. Thrombosis and Haemostasis 2013; 110(1): 23–30.Google Scholar
Roqué, H, Paidas, MJ, Funai, EF, Kuczynski, E, Lockwood, CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thrombosis and Haemostasis 2004; 91: 290–295.Google Scholar
Sugiura-Ogasawara, M, Ozaki, Y, Kitaori, T, Suzumori, N, Obayashi, S, Suzuki, S. Live birth rate according to maternal age and previous number of recurrent miscarriages. American Journal of Reproductive Immunology 2009; 62(5): 314–319.Google Scholar
Lund, M, Kamper-Jørgensen, M, Nielsen, HS et al. Prognosis for live birth in women with recurrent miscarriage. Obstetrics and Gynecology 2012; 119(1): 37–43.CrossRefGoogle ScholarPubMed
de Jong, PG, Kaandorp, SP, Kool, RO et al. Time to live birth in women with recurrent miscarriage and inherited thrombophilia. Abstracts of the XXV Congress of the International Society on Thrombosis and Hemostasis, June 20–25. Journal of Thrombosis and Hemostasis 2015; 13: 1–1090Google Scholar
De Jong, PG, Kaandorp, S, Di Nisio, M, Goddijn, M, Middeldorp, S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database of Systematic Reviews 2014; (7): CD004734.Google Scholar
Rodger, MA, Hague, WM, Kingdom, J et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): A multinational open-label randomised trial. Lancet 2014; 384(9955): 1673–1683.CrossRefGoogle Scholar
Visser, J, Ulander, VM, Helmerhorst, FM et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia – HABENOX*: A randomised multicenter trial. Thrombosis and Hemostasis 2011; 105(17): 295–301.Google Scholar
Clark, P, Walker, ID, Langhorne, P et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. Blood 2010; 115(21): 4162–4167.CrossRefGoogle ScholarPubMed
Kaandorp, SP, Goddijn, M, van der Post, JAM et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. New England Journal of Medicine 2010; 362: 1586–1596.Google Scholar
Baglin, T, Gray, E, Greaves, M et al. Clinical guidelines for testing for heritable thrombophilia. British Journal of Haematology 2010; 149: 209–220.CrossRefGoogle ScholarPubMed
Bates, S, Greer, IA, Middeldorp, S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141.Google Scholar
Pasquier, E, de Saint Martin, L, Bohec, C et al. Enoxaparin for prevention of unexplained recurrent miscarriage : a multicenter randomized double-blind placebo-controlled trial. Blood 2015; 125(14): 2200–2205.Google Scholar
Schleussner, E, Kamin, G, Seliger, G et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss. Annals of Internal Medicine 2015; 162(9): 601.CrossRefGoogle ScholarPubMed
De Jong, PG, Quenby, S, Bloemenkamp, KW et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia – study protocol for a randomized controlled trial. Trials 2015; 16(1): 208.CrossRefGoogle ScholarPubMed
Middeldorp, S. Anticoagulation in pregnancy complications. Hematology 2014; 1: 393–399.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×